The present disclosure relates to malware detection capabilities of network security devices and, more specifically, to testing and comparing of malware detection capabilities of network security devices.
Enterprise network administrators desiring to evaluate commercially available malware detection capabilities of network security devices may often conduct tests to determine efficacy of one or more malware detection solutions of the devices. These tests may be conducted before selection of one of the solutions for purchase or from time to time after solution procurement to assure continued efficacy of malware detection as the threat landscape changes. The testing may require using ‘live’ malware for realistic and accurate evaluation. As such, it is vital that the testing be conducted safely without the potential to infect the enterprise's own network and its IT infrastructure.
Typically, these tests are conducted by testing commodity (common and well known) malware in the selected malware detection solutions to assess whether the solutions detect the malware. Unfortunately, these tests can produce inaccurate results that do not reveal hidden deficiencies in the real-world malware detection capabilities of the detection solutions. For instance, some of the tested solutions may detect malware attacks based on pre-determined signatures or characteristics, such as whether the attacks match well known virus signatures, or whether they originate from black-listed domains (i.e., domains associated with known malware). Such detection solutions are unlikely to succeed in ‘real’ use of an actual ‘in production’ computer network, where the solutions must detect and protect against ‘zero day’ and other advanced malware.
Zero day attacks, by definition, have not been detected before and thus have no known signatures or known characteristics; accordingly, such signature-based solutions would fail to detect them. Moreover, advanced malware may coopt and use previously whitelisted domains, i.e., domains not previously known to be malicious; accordingly, solutions relying on domain-identification techniques would fail to detect them. Finally, advanced malware is often polymorphic, and thus has signatures and superficial characteristics that change over time while retaining core malicious functions, which, once again, may escape detection by solutions relying on pre-determined information. To accurately assess the effectiveness of malware detection solutions, attacks need to be tested in a manner as consistent as possible with real-world attacks on the enterprise (i.e., private) network including use of advanced malware.
It is often desirable to test detection solutions for other purposes and in other circumstances as well. For example, a detection solution vendor or manufacturer may test new releases or models of its detection solutions against prior releases and models (from the same manufacturer or from different companies) by way of comparison testing and/or to demonstrate enhanced detection capabilities.
The above and further advantages of the embodiments herein may be better understood by referring to the following description in conjunction with the accompanying drawings in which like reference numerals indicate identically or functionally similar elements, of which:
The embodiments herein are directed to a testing technique to test and compare malware detection capabilities of network security devices and other cyber-attack security devices, such as those commercially available from a variety of cyber-security vendors. Testing is conducted on a plurality of test samples in a “blind” fashion, where the security devices do not know beforehand whether the test samples are “live” malware or benign network traffic. The test samples are received from a remote server and potentially represent malicious attacks against a testing network. Notably, for truly blind testing, embodiments of the testing technique employ a mixture of malware and benign test samples, as well as addressing subterfuge, to prevent the security devices from being able to reliably determine maliciousness of the test samples based on a source of any of the samples.
In one or more embodiments, a virtualized endpoint running on a test console, e.g., a computer, connected to the testing network of a testing environment generates and sends one or more request messages (requests) to acquire a plurality (e.g., mixture) of test samples from a database of samples stored in a secure data store of the testing environment. Each request includes an indicator, e.g., a uniform resource locator (URL), of a domain that may or may not be known to be associated with a source of malware. More specifically, the URL's may each correspond to a well-known and common (i.e., “clean” or “whitelisted”) domain not generally associated with a malicious server. In other embodiments, the URL's may correspond to a mixture of such whitelisted domains and “dirty” or “blacklisted” domains known to be associated with a malicious server. Illustratively, the request is modified at a proxy of a gateway connected to the testing network to direct the request to a remote server storing the database of samples, while maintaining the URL as an alias domain of the request. The request is forwarded to a switch of the testing network that connects the test console and the security devices to provide communication with the remote server, which may be located external to the testing network and accessed, e.g., via a public network. The switch mirrors (i.e., provides copies of) the request to the security devices, illustratively “units under test” (UUTs), such as one or more malware detection systems, which may be equipped with counter-evasion technology configured to detect malware developed to avoid detection. According to the testing technique, the proxy may be used to obscure source/destination address information of communications (i.e., addressing subterfuge) with the remote server so that simplistic malware detection by, e.g., Internet address blacklisting, is unreliable for the UUTs to detect whether the communication has malware.
The remote server receives and parses each request for credentials to authenticate the virtualized endpoint as entitled to receive one or more test samples indicated in the request. The remote server then returns a response message (response) associated with each request addressed to the virtualized endpoint, wherein the response includes the one or more test samples of the mixture of malicious and benign test samples, each having at least one malware or benign object for processing by the virtualized endpoint. A copy of the response to the request is also provided to each UUT, e.g., via the switch. The virtualized endpoint processes the objects while each UUT performs its own processing of the objects to detect whether the objects are malware or benign. In some embodiments, and depending on the type of UUT being tested, each UUT may monitor and track the request-response message traffic (i.e., both inbound and outbound traffic) flowing between the gateway and remote server. The UUT may attempt, depending on its capabilities, to match the destination address (e.g., URL) of such outbound traffic (e.g., the request message) and/or the source address (e.g., URL) of such inbound traffic (e.g., response message) against a blacklist of known malicious servers. However, any attempt by the UUT to ascribe maliciousness to the alias domain for purposes of Internet address blacklisting of the destination of the request or the source of the response may be ineffective (i.e., unreliable indicator of malware) because of the mixture of malicious and benign objects contained in the response(s) and because of the mixture of clean and dirty alias domains.
During processing by the virtualized endpoint, the object may seek additional content, such as a malicious package not included in the object. The virtualized endpoint may generate further requests to obtain such additional content from one or more network locations, e.g., identified by one or more URLs specified by the object. The UUT may process the object and additional content to determine whether the object and additional content are malicious. Thereafter, each UUT may indicate whether an object (and additional content) is malware or benign.
Based on the reports of the UUTs, the test application issues its own report to compare and contrast detection efficacy of the UUT's. In an embodiment, the report may include information as to whether each UUT correctly identified samples as malicious or benign or incorrectly (i.e., falsely) identified samples as malicious or benign (false positives and false negatives, respectively), as well as a vector (e.g., email, web) used to deliver the sample and a sample type (e.g., object, flow, multi-flow).
In an embodiment, the endpoints may illustratively include, e.g., client/server desktop computers, laptop/notebook computers, process controllers, medical devices, data acquisition devices, mobile devices, such as smartphones and tablet computers, and/or any other intelligent electronic device having network connectivity that may be configured to implement a virtualization system. The nodes illustratively communicate by exchanging packets or messages (i.e., network/message traffic) according to a predefined set of protocols, such as the Transmission Control Protocol/Internet Protocol (TCP/IP); however, it should be noted that other protocols, such as the HyperText Transfer Protocol Secure (HTTPS), File Transfer Protocol (FTP) and various email protocols, may be advantageously used with the embodiments herein. In the case of private network 130, the intermediate node 150 may include a firewall or other network computing device configured to limit or block certain network traffic in an attempt to protect the endpoints from unauthorized users and attacks.
The memory 220 may include a plurality of locations that are addressable by the CPU(s) 212 and the network inter face(s) 214 for storing software program code (including application programs 240 and, as described below for one or more embodiments of a virtualized endpoint of the test console, an agent 250) and data structures (e.g., data logs), not shown, associated with the embodiments described herein. The CPU 212 may be embodied as a hardware processor including processing elements or logic adapted to execute the software program code and application programs, and manipulate the data structures. Exemplary CPUs may include families of instruction set architectures based on the x86 CPU and the x64 CPU. An operating system 230, portions of which are typically resident in memory 220 and executed by the CPU, functionally organizes the node by, inter alia, invoking operations in support of the software program code and application programs 240 executing on the node. Illustratively, the software program code may be implemented as processes of the operating system 230. As used herein, a process is an instance of software program code (e.g., an application program 240) executing in the operating system that may be separated (decomposed) into a plurality of threads, wherein each thread is a sequence of execution within the process.
It will be apparent to those skilled in the art that other types of processing elements and memory, including various computer-readable media, may be used to store and execute program instructions pertaining to the embodiments described herein. Also, while the embodiments herein are described in terms of software program code and application programs stored in memory, alternative embodiments also include the code/programs being embodied as modules consisting of hardware, software, firmware, or combinations thereof.
The embodiments herein are directed to a testing technique to test and compare malware detection capabilities of network security devices and other cyber-attack security devices, such as those commercially available from a variety of cyber-security vendors. Testing is conducted on a plurality of test samples in a “blind” fashion, where the security devices do not know beforehand whether the test samples are “live” malware or benign network traffic. The test samples are received from a remote server and potentially represent malicious attacks against a testing network. Notably, for truly blind testing, embodiments of the testing technique employ a mixture of malware and benign test samples, as well as addressing subterfuge, to prevent the security devices from being able to reliably determine maliciousness of the test samples based on a source of any of the samples.
The malware may be of any level of sophistication, from commodity malware (such as computer viruses, worms, Trojans, or spyware) to advanced malware. As used herein, advanced malware may be of any type of sophisticated malware, such as (i) zero day malware that have not been previously detected and thus have no known signatures or characteristics; (ii) polymorphic malware that changes its appearance or behavior, including its signature, over time while retaining its core malicious functions, thus avoiding matches against a signature database; and/or (iii) targeted malware that targets a particular user or node on an enterprise network and that may not match signatures of known common malware. The advanced malware may be contained for example in a single downloaded webpage or email, or may be delivered in multiple stages such as a downloaded webpage or email including a link (URL) to a downloadable malware package. Moreover, the advanced malware may have built-in evasion technology configured to detect whether it is being processed in a detection environment and, if so, deactivate or postpone activation (hibernate) to avoid detection. Accordingly, in order to detect malware reliably, the malware detection systems may be configured with capabilities to detect advanced malware even if delivered in multiple stages while avoiding triggers (e.g., events) that may cause the malware to evade detection.
The switch 330 connects the test console 320 and the UUT's 340 to provide communication with the remote server 360, which may be located external to the testing network 310 and accessed, e.g., via the public network 120. The switch 330 may be, for example, hardware or a virtual switch provided by executable software of the test console 320. In alternative embodiments, though not shown in detail, it will be understood that the testing network 310 and the remote server 360 may be located in the same private network (e.g., in separate sub-networks of a single private network of an enterprise), or in separate private networks (e.g., first and second private networks of first and second enterprises, respectively) coupled together by a communication link such as a public network (e.g., the Internet), or the testing network may be in a private network and the remote server may be hosted in a public network. The switch 330 may be located operationally directly behind a firewall 350, router or other network device of the testing network 310 and may include logic (e.g., one or more mirroring ports) equipped to copy incoming packets (messages) received by the testing network 310 from the remote server 360, and provide the incoming messages (copies) to the test console 320 and each UUT 340. In an alternative embodiment, a UUT, such as anti-virus software or a detection agent (e.g., of the type described with respect to agent 250), may be included in the virtualized endpoint 324 to facilitate testing of endpoint-based malware detection, as described further herein.
In an embodiment, the MDS may be included within a special-purpose, malware detection appliance or a component in a general purpose computing device. As used herein, an appliance may be embodied as any type of general-purpose or special-purpose computer, including a dedicated electronic computing device, adapted to implement a variety of software architectures relating to exploit and malware detection functionality. The term “appliance” should therefore be taken broadly to include such arrangements, in addition to any systems or subsystems configured to perform a management function for exploit and malware detection, and associated with other equipment or systems, such as a network computing device interconnecting the WANs and LANs. The MDS may be available via a local network connection or remotely through the internet. The MDS may include static analysis logic that may identify suspicious or malicious characteristics of an object, statically (operable without executing the object). Additionally, the MDS may utilize dynamic analysis logic to process suspicious objects in an instrumented (i.e., monitored), virtual machine capable of detecting behaviors of the suspicious objects during processing. The dynamic analysis logic may be configured with (and run) an operating system and one or more applications (collectively, a “software profile”) that the suspicious object may expect or need for effective processing. That is, the software profile may include the same type of software that runs on the virtualized endpoint to execute the object. By so doing, the software environment in which the virtualized endpoint monitors the suspicious behaviors may be replicated in the software profile run on the virtual machine of the MDS. In this way, object behaviors that may be exhibited only in the presence of those applications may be detected. In another embodiment, the software profile may include a different type of software (e.g., different vendor or version) that runs on the virtualized endpoint to execute the object, to determine the presence of malware within a different runtime environment, or plural software profiles (for example, the same and different from that run on the endpoint). The MDS may also include a component that may combine the results of the static and dynamic analyses to classify the object as malicious or benign.
The test console 320 may be configured with a test application 322, a virtualized endpoint 324 and a gateway 326. The test application 322 runs on the test console 320 to permit the test administrator to select from a database of test samples (one or more malicious or benign objects) available from the remote server 360. For instance, the test administrator may be presented with a list of test samples on the computer display (user interface 215) of the test console from which to choose by selecting, e.g., via mouse click, one or more identifiers associated with one or more samples and submitting the identifiers as part of a request message (request). Illustratively, the test administrator may select an identifier associated with an individual malicious or benign sample, or an identifier associated with a predetermined mixture of malicious and benign samples. Each identifier may be a domain or uniform resource locator (URL), which has a one-to-one (1:1) association with the sample or mixture of samples. The URL's may each correspond to a well-known and common (i.e., “clean” or “whitelisted”) domain (e.g., Microsoft.com or Google.com) which, while not likely to have been blacklisted as a malicious server, may nonetheless have been hijacked and used to download malware. In other embodiments, the URL's may correspond to a mixture of such whitelisted domains and “dirty” or “blacklisted” domains known to be associated with one or more malicious servers. In an embodiment, the administrator may be presented with one or more test suites having a pre-arranged selection of test samples (e.g., a pre-arranged selection of malicious and benign test samples) arranged according to a level of test sophistication designed to measure detection capabilities of the UUTs (e.g., percentage of samples correctly detected as benign or malicious).
The test application 322 may instantiate (which should be read to include causing the instantiation of) the virtualized endpoint 324 as a virtual machine running on the test console 320 to simulate one or more actual endpoints on the enterprise network that may be vulnerable to the malware. The virtualized endpoint 324 of the test console 320 thus serves as a “victim” node for the test samples, while providing for safe, “sandboxed” processing. Additionally, by simulating an actual endpoint, the virtualized endpoint 324 may effectively simulate a “normal” computer network node, and thus serve to counter (e.g., suppress) evasion technology of advanced malware. To that end, the virtualized endpoint 324 may serve as a source of one or more requests for the samples, i.e., mimicking a “real” endpoint, configured to generate and send each request to a destination intended by the URL of the request, but which is redirected by the gateway 326 to the remote server 360. In this regard, the virtualized endpoint 324 may initiate establishment of a communication session with the remote server 360 (via the gateway 326) to acquire the sample, e.g., an advanced malware sample. The advanced malware sample may be a single object or a group of related objects (e.g., messages) organized as a flow during a single communication session between the virtualized endpoint 324 and the remote server 360 or as a set of flows (multi-flow attack). A multi-flow attack is a coordinated strike delivering various objects (including at least one malicious object) over multiple stages and multiple flows, sometimes across multiple vectors. Many commercially available cyber-security solutions analyze these stages separately; unfortunately, they may appear benign when viewed independently, limiting the security solutions' ability to detect multi-flow attacks. Better cyber-security solutions can detect and analyze the totality of a multi-flow attack, recognizing and correlating the related flows. For instance, a request may be initiated (generated) by the virtualized endpoint 324 and include the URL (identifier) as an alias domain. The remote server 360 may provide the response to the request in one or more response messages containing an object, a flow or set of flows, during a same communication session (in the case of an object or flow) or during a set of communication sessions (in the case of a multi-flow attack). In response to a further request from the virtualized endpoint 324 for additional content, as described elsewhere herein, the remote server may provide additional responses. UUT's equipped to detect multi-flow attacks are typically designed to capture all the related flows, and delay completion of processing for malware detection until they are received and can be processed together.
In some embodiments, the test application 322 may generate a request seeking a single malware sample, which is associated with not one but two (or more) URLs. These may include a first URL associated with a known (i.e., previously determined) malicious webserver and thus quite likely contained in an address blacklist of an UUT, and a second URL having a well-known and common domain not known to be associated with a malicious server and thus not likely blacklisted. A response to the request may include a first copy of the malware served with the first, known malicious URL, and a second copy of the malware served with the second, misleadingly benign appearing URL to enable the employment of addressing subterfuge in accordance with the testing technique described herein. This enables testing of the capability of the UUT's to detect advanced malware, as will be describe in greater detail below.
The gateway 326 may be embodied as a translation application (redirecting the request to the remote server) running in another (i.e., second) virtual machine of the test console 320. Alternatively, the gateway may be embodied as a node within the testing network. Illustratively, the gateway 326 intermediates requests and responses (message traffic) between the virtualized endpoint 324 and the remote server 360 for the communication session or sessions), and, to that end, redirects that message traffic to the remote server 360 and virtualized endpoint 324 as appropriate. In one or more embodiments, e.g., using the HTTPS protocol, the communication session is illustratively established between the gateway 326 and the remote server 360, and the virtualized endpoint 324 communicates with the gateway 326 via an internal connection (e.g., a virtualized bridge) within the test console 320. Accordingly, the gateway serves as a source device for the request-response message traffic for the communication session. In an embodiment, the gateway may act as a protection layer adapted to harden the testing network by restricting (e.g., filtering) communication according to a specific configuration. That is, the gateway may be configured, e.g., via one or more firewall rules, to limit communication (e.g., allow only specific protocols, such as HTTPS/HTTP), to be exchanged with the test console so as to prevent malicious message traffic using unrecognized or custom protocols that are often employed by malware. Illustratively, if the message traffic occurs in accordance with a custom communication protocol, such communication may or may not be allowed.
In order to mimic real-world attack scenarios that often include advanced malware designed to avoid detection by unsophisticated malware detection solutions, such as Internet address blacklisting of malicious domains (relied on by many commercially available malware detection technologies), the testing technique employs addressing subterfuge on the request (packet) using one or more proxies embodied as proxy software 328, such as the Squid proxy software available as open source from www.squid-cache.org. The proxy may be used to obscure source/destination address information of communications (i.e., addressing subterfuge) with the remote server 360 so that simplistic malware detection by, e.g., Internet address blacklisting, is unreliable for the UUT's 340 as is the case in many real-world scenarios. Illustratively, an instance of the proxy software 328 may be employed and executed at the gateway 326 of the test console 320 to modify request packet information (headers) so that the request is re-directed to the remote server 360 for response rather than the URL (alias domain) contained in the request. That is, an original Internet address (e.g., IP address) of the request associated with the URL is altered (modified) to an Internet address of the remote server, thus re-directing the request to the remote server. For example, the gateway 326 may receive a request (e.g., get HTTPS request message) from the virtualized endpoint 324 that specifies a well-known and common URL as the alias (destination) domain of the request and the gateway (proxy software 328) may modify an appropriate header of the request to direct the request to the remote server 360.
Referring again to
In an embodiment, the content engine 366 may also retrieve from the sample database indicators of compromise (IOC's) (e.g., behavioral features) associated with the test sample or samples, e.g., in response to selection of the URL by the test administrator. The IOC's may be sent to the test application 322 in a message separate from the sample or samples, whether proximate in time to the message containing the sample or samples or at a later time, such as during testing of the samples by the UUTs. IOC's received by the test administrator may be pre-determined from previous monitoring (i.e., observed behavior) of the associated test samples in an environment similar to that of the endpoint. As such, the IOC's represent expected behaviors of the test samples that indicate compromise (i.e., identify potentially malicious activity) of an endpoint. The purpose and use of the IOC's are described below.
Referring again to
In those cases in which IOC's associated with a sample/object are received from the content engine 366, upon completion of processing by the virtualized endpoint 324, the test application 322 may inspect (e.g., scan) the virtualized endpoint using observed IOC's of the objects to determine whether the virtualized endpoint was compromised or not. In some embodiments, the test application 322 can cause an endpoint detection agent 250 (
In one or more embodiments, in order to monitor for behaviors during processing of an object within the virtualized endpoint 324, the virtualized endpoint includes an endpoint detection agent 250 (
Illustratively, the UUT's 340 are configured to receive the copied content, e.g., receive the one or more objects and additional content (e.g., messages) from the switch 330 and process the objects and additional content in normal operation to determine whether the objects and additional content are malicious. In typical commercially-available malware detection systems, the UUT's 340 may treat the additional objects as new objects for separate analysis or may treat them as objects related to objects from a prior flow for analysis as part of a potential multi-flow attack.
Some commercially-available malware detection systems may be adapted (provisioned) to submit cyber-security alerts with details regarding malware detections (and other results) to a conventional third-party or open source data aggregation product such as a SIEM (Security Information and Event Management). The aggregation product can often collect, analyze, index and correlate such real-time data in a searchable repository for later presentation to users/consumers. The virtualized endpoint of the present embodiments may be equipped with an application program interface for at least one such data aggregation product. When any of the UUT's attempts to issue alerts by sending the alert data out over the testing network, the switch provides the alert data to the virtualized endpoint, which is then processed by the test application to extract the detection information contained in the data for use in comparison of detection results from the UUT's. The alert data typically is not communicated outside the testing network.
It should be noted that
In the case of a multi-flow attack wherein the UUT's may detect and block a particular stage or flow of the multiple related flows, the test application 322 may analyze logs of the gateway 326 to determine whether other stages or flows of the multiple related flows may have bypassed (i.e., failed) detection by the UUT's and reached the console. Where any of the other stages or flows did manage to avoid detection, the test application 322 can report such detection failure as part of its UUT's efficacy assessment.
Each UUT may track (receive) the request-response message traffic between the gateway 326 and the remote server 360, which maintains the URL as the alias domain (source or destination, as the case may be) or, depending on the embodiment, just the response message traffic to the gateway 326 from the remote server 360, which maintains the URL as the alias domain (source). In other embodiments, the UUT may track the session id of the communication session for the request-response message traffic or the source IP address of the request/response which maintains the alias domain as the URL destination/source, respectively. However, any attempt by the UUT to ascribe maliciousness to the source domain or source IP address for purposes of Internet address blacklisting of the source of the response (and similarly for the request message) may be ineffective (i.e., unreliable indicator of malware) because of the mixture of malicious and benign objects contained in the response. In essence, the testing technique measures whether processing by the UUT is performed on the objects contained in the payload of the response rather than on the address information contained in the header fields of the request and/or response. That is, malware detection techniques employed by UUT's that rely largely on header metadata information (e.g., source and destination IP addresses 410, 420, 510, 520, as well as session ID 430, 530 and URL 452) in the request/response may be revealed by the testing technique in the form of a higher percentage of false positive and false negative malware detection scores versus malware detection techniques that analyze the response payload.
The UUT's 340 may issue reports/alerts as to their findings and results, which may be transmitted to the test application 322 of the test console 320. The test application 322 may assess the reported results, and determine the efficacy (e.g., a malware detection score) of each UUT 340 in correctly determining whether the received objects of the samples 542 are malicious or benign. The test application 322 may also present the results of the UUT's analysis in more detail, including the characteristics and behaviors observed for each sample, on which the malware determination is based. The test application 322 may generate a report on the efficacy and comparison of detection results of the UUTs (including, for example, where applicable, behaviors of the samples observed during their execution by the UUTs). This report may be presented to a user or administrator via the user interface 215 on the console's computer display. In an embodiment, the report may include information as to whether the UUT's 340 falsely identified samples as malicious and benign (false positives and false negatives, respectively), as well as the vector (e.g., email, web) used in an attack and a sample type (e.g., object, flow, multi-flow). The report may also include information with respect to a level of sophistication of malware in the samples.
At step 612, a response to the request is generated at the remote server, wherein the response includes the test sample or samples, each having at least one malware or benign object. The response may include, for example, a test sample or samples in the form of a webpage to be opened by a web browser on the virtualized endpoint. In some embodiments, the response may include, for example, a sample or samples in the form of an email or email attachment, in which an embedded URL may link to malware or benign content, and the UUT's must simulate user interaction to cause the embedded URL to be activated. At step 614, the response is returned to the virtualized endpoint via the switch where, at step 616, a copy of the response to the request is provided to each UUT. At step 618, each object included in the response is processed at the virtualized endpoint and, at step 620, in this embodiment, each UUT also processes (e.g., runs static and/or behavioral analysis) the object (e.g., a copy thereof) to detect whether the object is malware or benign. As noted, in some embodiments, each UUT may track the request-response message traffic between the virtual endpoint and remote server which maintains the alias domain for the response. However, any attempt by the UUT to ascribe maliciousness to the alias domain for purposes of Internet address blacklisting of the destination address of the request message or the source address of the response may be ineffective (i.e., unreliable to detect malware) because of the inclusion of a malicious or benign object contained in the response and, in other embodiments (or test configurations), the use of both clean and dirty alias domains that bear no relationship for purposes of the testing to whether the samples are malware or benign.
At step 622, each UUT generates a report of detection of the object as malware or benign. At step 624, the test application can report on the efficacy of the UUT's by comparing and contrasting the detections of the UUT's as reported in step 622. The report of the test application can be provided (generated) by a computer display or other human-readable (e.g., graphical and/or textural) or machine-readable output of the user interface 215 of the test console 320. As noted above, a malware sample can be associated with not one but two URLs, including a first URL recognizable as associated with a known malicious webserver and thus quite likely contained in an address blacklist, and a second URL not known to be associated with a malicious server and thus not likely blacklisted. Where one of the UUT's, for example, only detects the former case of the known malicious server, the report of the test application may expose the deficiency of that UUT with regard to detection of advance (e.g., zero-day) malware for which no preexisting blacklist entry can exist. Moreover, in some embodiments, the report of the test application may include information regarding the ability of the UUT's to detect the IOC's as provided by the content engine and/or as experienced by (and monitored in) the virtualized endpoint during processing of the object. The procedure ends at step 626.
While there have been shown and described illustrative embodiments of the invention, it is to be understood that various other adaptations and modifications may be made within the spirit and scope of the invention. For example, embodiments have been shown and described herein with relation to comparing the detection capabilities of the various commercially available solutions intended to be deployed as network security devices at the periphery of networks, as shown for UUT's 340 of
For example, each UUT 345 within the virtualized endpoint may be a convention anti-virus program that scans incoming network traffic against a database of signatures or another type of endpoint detection agent that monitors processes behaviors for indicators of compromise of the virtualized endpoint, and generate alerts. Each endpoint-located UUT 345 may be evaluated and compared against another endpoint-located UUT (not shown) or against one or more UUT's 340 located outside the virtual endpoint, as shown in
The foregoing description has been directed to specific embodiments. It will be apparent, however, that other variations and modifications may be made to the described embodiments, with the attainment of some or all of their advantages. For instance, it is expressly contemplated that the components and/or elements described herein can be implemented as software encoded on a tangible (non-transitory) computer-readable medium (e.g., disks, electronic memory, and/or CDs) having program instructions executing on a computer, hardware, firmware, or a combination thereof. Moreover, the embodiments or aspects thereof can be implemented in hardware, firmware, software, or a combination thereof. In the foregoing description, for example, in certain situations, terms such as “engine,” “component” and “logic” are representative of hardware, firmware and/or software that is configured to perform one or more functions. As hardware, engine (or component/logic) may include circuitry having data processing or storage functionality. Examples of such circuitry may include, but is not limited or restricted to a microprocessor, one or more processor cores, a programmable gate array, a microcontroller, an application specific integrated circuit, semiconductor memory, or combinatorial logic. Accordingly this description is to be taken only by way of example and not to otherwise limit the scope of the embodiments herein. Therefore, it is the object of the appended claims to cover all such variations and modifications as come within the true spirit and scope of the embodiments.
Number | Name | Date | Kind |
---|---|---|---|
4292580 | Ott et al. | Sep 1981 | A |
5175732 | Hendel et al. | Dec 1992 | A |
5319776 | Hile et al. | Jun 1994 | A |
5440723 | Arnold et al. | Aug 1995 | A |
5490249 | Miller | Feb 1996 | A |
5657473 | Killean et al. | Aug 1997 | A |
5802277 | Cowlard | Sep 1998 | A |
5842002 | Schnurer et al. | Nov 1998 | A |
5960170 | Chen et al. | Sep 1999 | A |
5978917 | Chi | Nov 1999 | A |
5983348 | Ji | Nov 1999 | A |
6088803 | Tso et al. | Jul 2000 | A |
6092194 | Touboul | Jul 2000 | A |
6094677 | Capek et al. | Jul 2000 | A |
6108799 | Boulay et al. | Aug 2000 | A |
6154844 | Touboul et al. | Nov 2000 | A |
6269330 | Cidon et al. | Jul 2001 | B1 |
6272641 | Ji | Aug 2001 | B1 |
6279113 | Vaidya | Aug 2001 | B1 |
6298445 | Shostack et al. | Oct 2001 | B1 |
6357008 | Nachenberg | Mar 2002 | B1 |
6424627 | Sorhaug et al. | Jul 2002 | B1 |
6442696 | Wray et al. | Aug 2002 | B1 |
6484315 | Ziese | Nov 2002 | B1 |
6487666 | Shanklin et al. | Nov 2002 | B1 |
6493756 | O'Brien et al. | Dec 2002 | B1 |
6550012 | Villa et al. | Apr 2003 | B1 |
6775657 | Baker | Aug 2004 | B1 |
6831893 | Ben Nun et al. | Dec 2004 | B1 |
6832367 | Choi et al. | Dec 2004 | B1 |
6895550 | Kanchirayappa et al. | May 2005 | B2 |
6898632 | Gordy et al. | May 2005 | B2 |
6907396 | Muttik et al. | Jun 2005 | B1 |
6941348 | Petry et al. | Sep 2005 | B2 |
6971097 | Wallman | Nov 2005 | B1 |
6981279 | Arnold et al. | Dec 2005 | B1 |
7007107 | Ivchenko et al. | Feb 2006 | B1 |
7028179 | Anderson et al. | Apr 2006 | B2 |
7043757 | Hoefelmeyer et al. | May 2006 | B2 |
7058822 | Edery et al. | Jun 2006 | B2 |
7069316 | Gryaznov | Jun 2006 | B1 |
7080407 | Zhao et al. | Jul 2006 | B1 |
7080408 | Pak et al. | Jul 2006 | B1 |
7093002 | Wolff et al. | Aug 2006 | B2 |
7093239 | van der Made | Aug 2006 | B1 |
7096498 | Judge | Aug 2006 | B2 |
7100201 | Izatt | Aug 2006 | B2 |
7107617 | Hursey et al. | Sep 2006 | B2 |
7159149 | Spiegel et al. | Jan 2007 | B2 |
7213260 | Judge | May 2007 | B2 |
7231667 | Jordan | Jun 2007 | B2 |
7240364 | Branscomb et al. | Jul 2007 | B1 |
7240368 | Roesch et al. | Jul 2007 | B1 |
7243371 | Kasper et al. | Jul 2007 | B1 |
7249175 | Donaldson | Jul 2007 | B1 |
7287278 | Liang | Oct 2007 | B2 |
7308716 | Danford et al. | Dec 2007 | B2 |
7328453 | Merkle, Jr. et al. | Feb 2008 | B2 |
7346486 | Ivancic et al. | Mar 2008 | B2 |
7356736 | Natvig | Apr 2008 | B2 |
7386888 | Liang et al. | Jun 2008 | B2 |
7392542 | Bucher | Jun 2008 | B2 |
7418729 | Szor | Aug 2008 | B2 |
7428300 | Drew et al. | Sep 2008 | B1 |
7441272 | Durham et al. | Oct 2008 | B2 |
7448084 | Apap et al. | Nov 2008 | B1 |
7458098 | Judge et al. | Nov 2008 | B2 |
7464404 | Carpenter et al. | Dec 2008 | B2 |
7464407 | Nakae et al. | Dec 2008 | B2 |
7467408 | O'Toole, Jr. | Dec 2008 | B1 |
7478428 | Thomlinson | Jan 2009 | B1 |
7480773 | Reed | Jan 2009 | B1 |
7487543 | Arnold et al. | Feb 2009 | B2 |
7496960 | Chen et al. | Feb 2009 | B1 |
7496961 | Zimmer et al. | Feb 2009 | B2 |
7519990 | Xie | Apr 2009 | B1 |
7523493 | Liang et al. | Apr 2009 | B2 |
7530104 | Thrower et al. | May 2009 | B1 |
7540025 | Tzadikario | May 2009 | B2 |
7546638 | Anderson et al. | Jun 2009 | B2 |
7565550 | Liang et al. | Jul 2009 | B2 |
7568233 | Szor et al. | Jul 2009 | B1 |
7584455 | Ball | Sep 2009 | B2 |
7603715 | Costa et al. | Oct 2009 | B2 |
7607171 | Marsden et al. | Oct 2009 | B1 |
7639714 | Stolfo et al. | Dec 2009 | B2 |
7644441 | Schmid et al. | Jan 2010 | B2 |
7657419 | van der Made | Feb 2010 | B2 |
7676841 | Sobchuk et al. | Mar 2010 | B2 |
7698548 | Shelest et al. | Apr 2010 | B2 |
7707633 | Danford et al. | Apr 2010 | B2 |
7712136 | Sprosts et al. | May 2010 | B2 |
7730011 | Deninger et al. | Jun 2010 | B1 |
7739740 | Nachenberg et al. | Jun 2010 | B1 |
7779463 | Stolfo et al. | Aug 2010 | B2 |
7784097 | Stolfo et al. | Aug 2010 | B1 |
7832008 | Kraemer | Nov 2010 | B1 |
7836502 | Zhao et al. | Nov 2010 | B1 |
7849506 | Dansey et al. | Dec 2010 | B1 |
7854007 | Sprosts et al. | Dec 2010 | B2 |
7869073 | Oshima | Jan 2011 | B2 |
7877803 | Enstone et al. | Jan 2011 | B2 |
7904959 | Sidiroglou et al. | Mar 2011 | B2 |
7908660 | Bahl | Mar 2011 | B2 |
7930738 | Petersen | Apr 2011 | B1 |
7937387 | Frazier et al. | May 2011 | B2 |
7937761 | Bennett | May 2011 | B1 |
7949849 | Lowe et al. | May 2011 | B2 |
7996556 | Raghavan et al. | Aug 2011 | B2 |
7996836 | McCorkendale et al. | Aug 2011 | B1 |
7996904 | Chiueh et al. | Aug 2011 | B1 |
7996905 | Arnold et al. | Aug 2011 | B2 |
8006305 | Aziz | Aug 2011 | B2 |
8010667 | Zhang et al. | Aug 2011 | B2 |
8020206 | Hubbard et al. | Sep 2011 | B2 |
8028338 | Schneider et al. | Sep 2011 | B1 |
8042184 | Batenin | Oct 2011 | B1 |
8045094 | Teragawa | Oct 2011 | B2 |
8045458 | Alperovitch et al. | Oct 2011 | B2 |
8069484 | McMillan et al. | Nov 2011 | B2 |
8087086 | Lai et al. | Dec 2011 | B1 |
8171553 | Aziz et al. | May 2012 | B2 |
8176049 | Deninger et al. | May 2012 | B2 |
8176480 | Spertus | May 2012 | B1 |
8201246 | Wu et al. | Jun 2012 | B1 |
8204984 | Aziz et al. | Jun 2012 | B1 |
8214905 | Doukhvalov et al. | Jul 2012 | B1 |
8220055 | Kennedy | Jul 2012 | B1 |
8225288 | Miller et al. | Jul 2012 | B2 |
8225373 | Kraemer | Jul 2012 | B2 |
8233882 | Rogel | Jul 2012 | B2 |
8234640 | Fitzgerald et al. | Jul 2012 | B1 |
8234709 | Viljoen et al. | Jul 2012 | B2 |
8239944 | Nachenberg et al. | Aug 2012 | B1 |
8260914 | Ranjan | Sep 2012 | B1 |
8266091 | Gubin et al. | Sep 2012 | B1 |
8286251 | Eker et al. | Oct 2012 | B2 |
8291499 | Aziz et al. | Oct 2012 | B2 |
8307435 | Mann et al. | Nov 2012 | B1 |
8307443 | Wang et al. | Nov 2012 | B2 |
8312545 | Tuvell et al. | Nov 2012 | B2 |
8321936 | Green et al. | Nov 2012 | B1 |
8321941 | Tuvell et al. | Nov 2012 | B2 |
8332571 | Edwards, Sr. | Dec 2012 | B1 |
8365286 | Poston | Jan 2013 | B2 |
8365297 | Parshin et al. | Jan 2013 | B1 |
8370938 | Daswani et al. | Feb 2013 | B1 |
8370939 | Zaitsev et al. | Feb 2013 | B2 |
8375444 | Aziz et al. | Feb 2013 | B2 |
8381299 | Stolfo et al. | Feb 2013 | B2 |
8402529 | Green et al. | Mar 2013 | B1 |
8464340 | Ahn et al. | Jun 2013 | B2 |
8479174 | Chiriac | Jul 2013 | B2 |
8479276 | Vaystikh et al. | Jul 2013 | B1 |
8479291 | Bodke | Jul 2013 | B1 |
8505094 | Xuewen | Aug 2013 | B1 |
8510827 | Leake et al. | Aug 2013 | B1 |
8510828 | Guo et al. | Aug 2013 | B1 |
8510842 | Amit et al. | Aug 2013 | B2 |
8516478 | Edwards et al. | Aug 2013 | B1 |
8516590 | Ranadive et al. | Aug 2013 | B1 |
8516593 | Aziz | Aug 2013 | B2 |
8522348 | Chen et al. | Aug 2013 | B2 |
8528086 | Aziz | Sep 2013 | B1 |
8533824 | Hutton et al. | Sep 2013 | B2 |
8539582 | Aziz et al. | Sep 2013 | B1 |
8549638 | Aziz | Oct 2013 | B2 |
8555391 | Demir et al. | Oct 2013 | B1 |
8561177 | Aziz et al. | Oct 2013 | B1 |
8566476 | Shiffer et al. | Oct 2013 | B2 |
8566946 | Aziz et al. | Oct 2013 | B1 |
8584094 | Dadhia et al. | Nov 2013 | B2 |
8584234 | Sobel et al. | Nov 2013 | B1 |
8584239 | Aziz et al. | Nov 2013 | B2 |
8595834 | Xie et al. | Nov 2013 | B2 |
8627476 | Satish et al. | Jan 2014 | B1 |
8635696 | Aziz | Jan 2014 | B1 |
8682054 | Xue et al. | Mar 2014 | B2 |
8682812 | Ranjan | Mar 2014 | B1 |
8689333 | Aziz | Apr 2014 | B2 |
8695096 | Zhang | Apr 2014 | B1 |
8713631 | Pavlyushchik | Apr 2014 | B1 |
8713681 | Silberman et al. | Apr 2014 | B2 |
8726392 | McCorkendale et al. | May 2014 | B1 |
8739280 | Chess et al. | May 2014 | B2 |
8776229 | Aziz | Jul 2014 | B1 |
8782792 | Bodke | Jul 2014 | B1 |
8789172 | Stolfo et al. | Jul 2014 | B2 |
8789178 | Kejriwal et al. | Jul 2014 | B2 |
8793278 | Frazier et al. | Jul 2014 | B2 |
8793787 | Ismael et al. | Jul 2014 | B2 |
8805947 | Kuzkin et al. | Aug 2014 | B1 |
8806647 | Daswani et al. | Aug 2014 | B1 |
8832829 | Manni et al. | Sep 2014 | B2 |
8850570 | Ramzan | Sep 2014 | B1 |
8850571 | Staniford et al. | Sep 2014 | B2 |
8881234 | Narasimhan et al. | Nov 2014 | B2 |
8881271 | Butler, II | Nov 2014 | B2 |
8881282 | Aziz et al. | Nov 2014 | B1 |
8898788 | Aziz et al. | Nov 2014 | B1 |
8935779 | Manni et al. | Jan 2015 | B2 |
8949257 | Shiffer et al. | Feb 2015 | B2 |
8984638 | Aziz et al. | Mar 2015 | B1 |
8990939 | Staniford et al. | Mar 2015 | B2 |
8990944 | Singh et al. | Mar 2015 | B1 |
8997219 | Staniford et al. | Mar 2015 | B2 |
9009822 | Ismael et al. | Apr 2015 | B1 |
9009823 | Ismael et al. | Apr 2015 | B1 |
9021085 | Jensen | Apr 2015 | B1 |
9027135 | Aziz | May 2015 | B1 |
9071638 | Aziz et al. | Jun 2015 | B1 |
9104867 | Thioux et al. | Aug 2015 | B1 |
9106630 | Frazier et al. | Aug 2015 | B2 |
9106694 | Aziz | Aug 2015 | B2 |
9118715 | Staniford et al. | Aug 2015 | B2 |
9159035 | Ismael et al. | Oct 2015 | B1 |
9171160 | Vincent et al. | Oct 2015 | B2 |
9176843 | Ismael et al. | Nov 2015 | B1 |
9189627 | Islam | Nov 2015 | B1 |
9195829 | Goradia et al. | Nov 2015 | B1 |
9197664 | Aziz et al. | Nov 2015 | B1 |
9223972 | Vincent et al. | Dec 2015 | B1 |
9225740 | Ismael et al. | Dec 2015 | B1 |
9241010 | Bennett et al. | Jan 2016 | B1 |
9251343 | Vincent et al. | Feb 2016 | B1 |
9262635 | Paithane et al. | Feb 2016 | B2 |
9268936 | Butler | Feb 2016 | B2 |
9275229 | LeMasters | Mar 2016 | B2 |
9282109 | Aziz et al. | Mar 2016 | B1 |
9292686 | Ismael et al. | Mar 2016 | B2 |
9294501 | Mesdaq et al. | Mar 2016 | B2 |
9300686 | Pidathala et al. | Mar 2016 | B2 |
9306960 | Aziz | Apr 2016 | B1 |
9306974 | Aziz et al. | Apr 2016 | B1 |
9311479 | Manni | Apr 2016 | B1 |
9330258 | Satish | May 2016 | B1 |
9355247 | Thioux et al. | May 2016 | B1 |
9356944 | Aziz | May 2016 | B1 |
9363280 | Rivlin et al. | Jun 2016 | B1 |
9367681 | Ismael et al. | Jun 2016 | B1 |
9398028 | Karandikar et al. | Jul 2016 | B1 |
9413774 | Liu | Aug 2016 | B1 |
9413781 | Cunningham et al. | Aug 2016 | B2 |
9426071 | Caldejon et al. | Aug 2016 | B1 |
9430646 | Mushtaq et al. | Aug 2016 | B1 |
9432389 | Khalid et al. | Aug 2016 | B1 |
9438613 | Paithane et al. | Sep 2016 | B1 |
9438622 | Staniford et al. | Sep 2016 | B1 |
9438623 | Thioux et al. | Sep 2016 | B1 |
9459901 | Jung et al. | Oct 2016 | B2 |
9467460 | Otvagin et al. | Oct 2016 | B1 |
9483644 | Paithane et al. | Nov 2016 | B1 |
9495180 | Ismael | Nov 2016 | B2 |
9497213 | Thompson et al. | Nov 2016 | B2 |
9507935 | Ismael et al. | Nov 2016 | B2 |
9516057 | Aziz | Dec 2016 | B2 |
9519782 | Aziz et al. | Dec 2016 | B2 |
9536091 | Paithane et al. | Jan 2017 | B2 |
9537972 | Edwards et al. | Jan 2017 | B1 |
9560059 | Islam | Jan 2017 | B1 |
9565202 | Kindlund et al. | Feb 2017 | B1 |
9591015 | Amin et al. | Mar 2017 | B1 |
9591020 | Aziz | Mar 2017 | B1 |
9594904 | Jain et al. | Mar 2017 | B1 |
9594905 | Ismael et al. | Mar 2017 | B1 |
9594912 | Thioux et al. | Mar 2017 | B1 |
9609007 | Rivlin et al. | Mar 2017 | B1 |
9626509 | Khalid et al. | Apr 2017 | B1 |
9628498 | Aziz et al. | Apr 2017 | B1 |
9628507 | Haq et al. | Apr 2017 | B2 |
9633134 | Ross | Apr 2017 | B2 |
9635039 | Islam et al. | Apr 2017 | B1 |
9641546 | Manni et al. | May 2017 | B1 |
9654485 | Neumann | May 2017 | B1 |
9661009 | Karandikar et al. | May 2017 | B1 |
9661018 | Aziz | May 2017 | B1 |
9674298 | Edwards et al. | Jun 2017 | B1 |
9680862 | Ismael et al. | Jun 2017 | B2 |
9690606 | Ha et al. | Jun 2017 | B1 |
9690933 | Singh et al. | Jun 2017 | B1 |
9690935 | Shiffer et al. | Jun 2017 | B2 |
9690936 | Malik et al. | Jun 2017 | B1 |
9736179 | Ismael | Aug 2017 | B2 |
9740857 | Ismael et al. | Aug 2017 | B2 |
9747446 | Pidathala et al. | Aug 2017 | B1 |
9756074 | Aziz et al. | Sep 2017 | B2 |
9773112 | Rathor et al. | Sep 2017 | B1 |
9781144 | Otvagin et al. | Oct 2017 | B1 |
9787700 | Amin et al. | Oct 2017 | B1 |
9787706 | Otvagin et al. | Oct 2017 | B1 |
9792196 | Ismael et al. | Oct 2017 | B1 |
9824209 | Ismael et al. | Nov 2017 | B1 |
9824211 | Wilson | Nov 2017 | B2 |
9824216 | Khalid et al. | Nov 2017 | B1 |
9825976 | Gomez et al. | Nov 2017 | B1 |
9825989 | Mehra et al. | Nov 2017 | B1 |
9838408 | Karandikar et al. | Dec 2017 | B1 |
9838411 | Aziz | Dec 2017 | B1 |
9838416 | Aziz | Dec 2017 | B1 |
9838417 | Khalid et al. | Dec 2017 | B1 |
9846776 | Paithane et al. | Dec 2017 | B1 |
9876701 | Caldejon et al. | Jan 2018 | B1 |
9888016 | Amin et al. | Feb 2018 | B1 |
9888019 | Pidathala et al. | Feb 2018 | B1 |
9910988 | Vincent et al. | Mar 2018 | B1 |
9912644 | Cunningham | Mar 2018 | B2 |
9912681 | Ismael et al. | Mar 2018 | B1 |
9912684 | Aziz et al. | Mar 2018 | B1 |
9912691 | Mesdaq et al. | Mar 2018 | B2 |
9912698 | Thioux et al. | Mar 2018 | B1 |
9916440 | Paithane et al. | Mar 2018 | B1 |
9921978 | Chan et al. | Mar 2018 | B1 |
9934376 | Ismael | Apr 2018 | B1 |
9934381 | Kindlund et al. | Apr 2018 | B1 |
9946568 | Ismael et al. | Apr 2018 | B1 |
9954890 | Staniford et al. | Apr 2018 | B1 |
9973531 | Thioux | May 2018 | B1 |
10002252 | Ismael et al. | Jun 2018 | B2 |
10019338 | Goradia et al. | Jul 2018 | B1 |
10019573 | Silberman et al. | Jul 2018 | B2 |
10025691 | Ismael et al. | Jul 2018 | B1 |
10025927 | Khalid et al. | Jul 2018 | B1 |
10027689 | Rathor et al. | Jul 2018 | B1 |
10027690 | Aziz et al. | Jul 2018 | B2 |
10027696 | Rivlin et al. | Jul 2018 | B1 |
10033747 | Paithane et al. | Jul 2018 | B1 |
10033748 | Cunningham et al. | Jul 2018 | B1 |
10033753 | Islam et al. | Jul 2018 | B1 |
10033759 | Kabra et al. | Jul 2018 | B1 |
10050998 | Singh | Aug 2018 | B1 |
10068091 | Aziz et al. | Sep 2018 | B1 |
10075455 | Zafar et al. | Sep 2018 | B2 |
10083302 | Paithane et al. | Sep 2018 | B1 |
10084813 | Eyada | Sep 2018 | B2 |
10089461 | Ha et al. | Oct 2018 | B1 |
10097573 | Aziz | Oct 2018 | B1 |
10104102 | Neumann | Oct 2018 | B1 |
10108446 | Steinberg et al. | Oct 2018 | B1 |
10121000 | Rivlin et al. | Nov 2018 | B1 |
10122746 | Manni et al. | Nov 2018 | B1 |
10133863 | Bu et al. | Nov 2018 | B2 |
10133866 | Kumar et al. | Nov 2018 | B1 |
10146810 | Shiffer et al. | Dec 2018 | B2 |
10148693 | Singh et al. | Dec 2018 | B2 |
10165000 | Aziz et al. | Dec 2018 | B1 |
10169585 | Pilipenko et al. | Jan 2019 | B1 |
10176321 | Abbasi et al. | Jan 2019 | B2 |
10181029 | Ismael et al. | Jan 2019 | B1 |
10191861 | Steinberg et al. | Jan 2019 | B1 |
10192052 | Singh et al. | Jan 2019 | B1 |
10198574 | Thioux et al. | Feb 2019 | B1 |
10200384 | Mushtaq et al. | Feb 2019 | B1 |
10210329 | Malik et al. | Feb 2019 | B1 |
10216927 | Steinberg | Feb 2019 | B1 |
10218740 | Mesdaq et al. | Feb 2019 | B1 |
10242185 | Goradia | Mar 2019 | B1 |
20010005889 | Albrecht | Jun 2001 | A1 |
20010047326 | Broadbent et al. | Nov 2001 | A1 |
20020018903 | Kokubo et al. | Feb 2002 | A1 |
20020038430 | Edwards et al. | Mar 2002 | A1 |
20020091819 | Melchione et al. | Jul 2002 | A1 |
20020095607 | Lin-Hendel | Jul 2002 | A1 |
20020116627 | Tarbotton et al. | Aug 2002 | A1 |
20020144156 | Copeland | Oct 2002 | A1 |
20020162015 | Tang | Oct 2002 | A1 |
20020166063 | Lachman et al. | Nov 2002 | A1 |
20020169952 | DiSanto et al. | Nov 2002 | A1 |
20020184528 | Shevenell et al. | Dec 2002 | A1 |
20020188887 | Largman et al. | Dec 2002 | A1 |
20020194490 | Halperin et al. | Dec 2002 | A1 |
20030021728 | Sharpe et al. | Jan 2003 | A1 |
20030074578 | Ford et al. | Apr 2003 | A1 |
20030084318 | Schertz | May 2003 | A1 |
20030101381 | Mateev et al. | May 2003 | A1 |
20030115483 | Liang | Jun 2003 | A1 |
20030188190 | Aaron et al. | Oct 2003 | A1 |
20030191957 | Hypponen et al. | Oct 2003 | A1 |
20030200460 | Morota et al. | Oct 2003 | A1 |
20030212902 | van der Made | Nov 2003 | A1 |
20030229801 | Kouznetsov et al. | Dec 2003 | A1 |
20030237000 | Denton et al. | Dec 2003 | A1 |
20040003323 | Bennett et al. | Jan 2004 | A1 |
20040006473 | Mills et al. | Jan 2004 | A1 |
20040015712 | Szor | Jan 2004 | A1 |
20040019832 | Arnold et al. | Jan 2004 | A1 |
20040047356 | Bauer | Mar 2004 | A1 |
20040083408 | Spiegel et al. | Apr 2004 | A1 |
20040088581 | Brawn et al. | May 2004 | A1 |
20040093513 | Cantrell et al. | May 2004 | A1 |
20040111531 | Staniford et al. | Jun 2004 | A1 |
20040117478 | Triulzi et al. | Jun 2004 | A1 |
20040117624 | Brandt et al. | Jun 2004 | A1 |
20040128355 | Chao et al. | Jul 2004 | A1 |
20040165588 | Pandya | Aug 2004 | A1 |
20040236963 | Danford et al. | Nov 2004 | A1 |
20040243349 | Greifeneder et al. | Dec 2004 | A1 |
20040249911 | Alkhatib et al. | Dec 2004 | A1 |
20040255161 | Cavanaugh | Dec 2004 | A1 |
20040268147 | Wiederin et al. | Dec 2004 | A1 |
20050005159 | Oliphant | Jan 2005 | A1 |
20050021740 | Bar et al. | Jan 2005 | A1 |
20050033960 | Vialen et al. | Feb 2005 | A1 |
20050033989 | Poletto et al. | Feb 2005 | A1 |
20050050148 | Mohammadioun et al. | Mar 2005 | A1 |
20050086523 | Zimmer et al. | Apr 2005 | A1 |
20050091513 | Mitomo et al. | Apr 2005 | A1 |
20050091533 | Omote et al. | Apr 2005 | A1 |
20050091652 | Ross et al. | Apr 2005 | A1 |
20050108562 | Khazan et al. | May 2005 | A1 |
20050114663 | Cornell et al. | May 2005 | A1 |
20050125195 | Brendel | Jun 2005 | A1 |
20050149726 | Joshi et al. | Jul 2005 | A1 |
20050157662 | Bingham et al. | Jul 2005 | A1 |
20050183143 | Anderholm et al. | Aug 2005 | A1 |
20050201297 | Peikari | Sep 2005 | A1 |
20050210533 | Copeland et al. | Sep 2005 | A1 |
20050238005 | Chen et al. | Oct 2005 | A1 |
20050240781 | Gassoway | Oct 2005 | A1 |
20050262562 | Gassoway | Nov 2005 | A1 |
20050265331 | Stolfo | Dec 2005 | A1 |
20050283839 | Cowburn | Dec 2005 | A1 |
20060010495 | Cohen et al. | Jan 2006 | A1 |
20060015416 | Hoffman et al. | Jan 2006 | A1 |
20060015715 | Anderson | Jan 2006 | A1 |
20060015747 | Van de Ven | Jan 2006 | A1 |
20060021029 | Brickell et al. | Jan 2006 | A1 |
20060021054 | Costa et al. | Jan 2006 | A1 |
20060031476 | Mathes et al. | Feb 2006 | A1 |
20060047665 | Neil | Mar 2006 | A1 |
20060070130 | Costea et al. | Mar 2006 | A1 |
20060075496 | Carpenter et al. | Apr 2006 | A1 |
20060095968 | Portolani et al. | May 2006 | A1 |
20060101516 | Sudaharan et al. | May 2006 | A1 |
20060101517 | Banzhof et al. | May 2006 | A1 |
20060117385 | Mester et al. | Jun 2006 | A1 |
20060123477 | Raghavan et al. | Jun 2006 | A1 |
20060143709 | Brooks et al. | Jun 2006 | A1 |
20060150249 | Gassen et al. | Jul 2006 | A1 |
20060161983 | Cothrell et al. | Jul 2006 | A1 |
20060161987 | Levy-Yurista | Jul 2006 | A1 |
20060161989 | Reshef et al. | Jul 2006 | A1 |
20060164199 | Gilde et al. | Jul 2006 | A1 |
20060173992 | Weber et al. | Aug 2006 | A1 |
20060179147 | Tran et al. | Aug 2006 | A1 |
20060184632 | Marino et al. | Aug 2006 | A1 |
20060191010 | Benjamin | Aug 2006 | A1 |
20060221956 | Narayan et al. | Oct 2006 | A1 |
20060236393 | Kramer et al. | Oct 2006 | A1 |
20060242709 | Seinfeld et al. | Oct 2006 | A1 |
20060248519 | Jaeger et al. | Nov 2006 | A1 |
20060248582 | Panjwani et al. | Nov 2006 | A1 |
20060251104 | Koga | Nov 2006 | A1 |
20060288417 | Bookbinder et al. | Dec 2006 | A1 |
20070006288 | Mayfield et al. | Jan 2007 | A1 |
20070006313 | Porras et al. | Jan 2007 | A1 |
20070011174 | Takaragi et al. | Jan 2007 | A1 |
20070016951 | Piccard et al. | Jan 2007 | A1 |
20070019286 | Kikuchi | Jan 2007 | A1 |
20070033645 | Jones | Feb 2007 | A1 |
20070038943 | FitzGerald et al. | Feb 2007 | A1 |
20070064689 | Shin et al. | Mar 2007 | A1 |
20070074169 | Chess et al. | Mar 2007 | A1 |
20070094730 | Bhikkaji et al. | Apr 2007 | A1 |
20070101435 | Konanka et al. | May 2007 | A1 |
20070128855 | Cho et al. | Jun 2007 | A1 |
20070142030 | Sinha et al. | Jun 2007 | A1 |
20070143827 | Nicodemus et al. | Jun 2007 | A1 |
20070156895 | Vuong | Jul 2007 | A1 |
20070157180 | Tillmann et al. | Jul 2007 | A1 |
20070157306 | Elrod et al. | Jul 2007 | A1 |
20070168988 | Eisner et al. | Jul 2007 | A1 |
20070171824 | Ruello et al. | Jul 2007 | A1 |
20070174915 | Gribble et al. | Jul 2007 | A1 |
20070192500 | Lum | Aug 2007 | A1 |
20070192858 | Lum | Aug 2007 | A1 |
20070198275 | Malden et al. | Aug 2007 | A1 |
20070208822 | Wang et al. | Sep 2007 | A1 |
20070220607 | Sprosts et al. | Sep 2007 | A1 |
20070240218 | Tuvell et al. | Oct 2007 | A1 |
20070240219 | Tuvell et al. | Oct 2007 | A1 |
20070240220 | Tuvell et al. | Oct 2007 | A1 |
20070240222 | Tuvell et al. | Oct 2007 | A1 |
20070250930 | Aziz et al. | Oct 2007 | A1 |
20070256132 | Oliphant | Nov 2007 | A2 |
20070271446 | Nakamura | Nov 2007 | A1 |
20080005782 | Aziz | Jan 2008 | A1 |
20080010683 | Baddour | Jan 2008 | A1 |
20080018122 | Zierler et al. | Jan 2008 | A1 |
20080028463 | Dagon et al. | Jan 2008 | A1 |
20080040710 | Chiriac | Feb 2008 | A1 |
20080046781 | Childs et al. | Feb 2008 | A1 |
20080066179 | Liu | Mar 2008 | A1 |
20080072326 | Danford et al. | Mar 2008 | A1 |
20080077793 | Tan et al. | Mar 2008 | A1 |
20080080518 | Hoeflin et al. | Apr 2008 | A1 |
20080086720 | Lekel | Apr 2008 | A1 |
20080098476 | Syversen | Apr 2008 | A1 |
20080120722 | Sima et al. | May 2008 | A1 |
20080134178 | Fitzgerald et al. | Jun 2008 | A1 |
20080134334 | Kim et al. | Jun 2008 | A1 |
20080141376 | Clausen et al. | Jun 2008 | A1 |
20080184367 | McMillan et al. | Jul 2008 | A1 |
20080184373 | Traut et al. | Jul 2008 | A1 |
20080189787 | Arnold et al. | Aug 2008 | A1 |
20080201778 | Guo et al. | Aug 2008 | A1 |
20080209557 | Herley et al. | Aug 2008 | A1 |
20080215742 | Goldszmidt et al. | Sep 2008 | A1 |
20080222729 | Chen et al. | Sep 2008 | A1 |
20080263665 | Ma et al. | Oct 2008 | A1 |
20080295172 | Bohacek | Nov 2008 | A1 |
20080301810 | Lehane et al. | Dec 2008 | A1 |
20080307524 | Singh et al. | Dec 2008 | A1 |
20080313738 | Enderby | Dec 2008 | A1 |
20080320594 | Jiang | Dec 2008 | A1 |
20090003317 | Kasralikar et al. | Jan 2009 | A1 |
20090007100 | Field et al. | Jan 2009 | A1 |
20090013408 | Schipka | Jan 2009 | A1 |
20090031423 | Liu et al. | Jan 2009 | A1 |
20090036111 | Danford et al. | Feb 2009 | A1 |
20090037835 | Goldman | Feb 2009 | A1 |
20090044024 | Oberheide et al. | Feb 2009 | A1 |
20090044274 | Budko et al. | Feb 2009 | A1 |
20090064332 | Porras et al. | Mar 2009 | A1 |
20090077666 | Chen et al. | Mar 2009 | A1 |
20090083369 | Marmor | Mar 2009 | A1 |
20090083855 | Apap et al. | Mar 2009 | A1 |
20090089879 | Wang et al. | Apr 2009 | A1 |
20090094697 | Provos et al. | Apr 2009 | A1 |
20090113425 | Ports et al. | Apr 2009 | A1 |
20090125976 | Wassermann et al. | May 2009 | A1 |
20090126015 | Monastyrsky et al. | May 2009 | A1 |
20090126016 | Sobko et al. | May 2009 | A1 |
20090133125 | Choi et al. | May 2009 | A1 |
20090144823 | Lamastra et al. | Jun 2009 | A1 |
20090158430 | Borders | Jun 2009 | A1 |
20090172815 | Gu et al. | Jul 2009 | A1 |
20090187992 | Poston | Jul 2009 | A1 |
20090193293 | Stolfo et al. | Jul 2009 | A1 |
20090198651 | Shiffer et al. | Aug 2009 | A1 |
20090198670 | Shiffer et al. | Aug 2009 | A1 |
20090198689 | Frazier et al. | Aug 2009 | A1 |
20090199274 | Frazier et al. | Aug 2009 | A1 |
20090199296 | Xie et al. | Aug 2009 | A1 |
20090228233 | Anderson et al. | Sep 2009 | A1 |
20090241187 | Troyansky | Sep 2009 | A1 |
20090241190 | Todd et al. | Sep 2009 | A1 |
20090265692 | Godefroid et al. | Oct 2009 | A1 |
20090271867 | Zhang | Oct 2009 | A1 |
20090300415 | Zhang et al. | Dec 2009 | A1 |
20090300761 | Park et al. | Dec 2009 | A1 |
20090328185 | Berg et al. | Dec 2009 | A1 |
20090328221 | Blumfield et al. | Dec 2009 | A1 |
20100005146 | Drako et al. | Jan 2010 | A1 |
20100011205 | McKenna | Jan 2010 | A1 |
20100017546 | Poo et al. | Jan 2010 | A1 |
20100030996 | Butler, II | Feb 2010 | A1 |
20100031353 | Thomas et al. | Feb 2010 | A1 |
20100037314 | Perdisci et al. | Feb 2010 | A1 |
20100043073 | Kuwamura | Feb 2010 | A1 |
20100054278 | Stolfo et al. | Mar 2010 | A1 |
20100058474 | Hicks | Mar 2010 | A1 |
20100064044 | Nonoyama | Mar 2010 | A1 |
20100077481 | Polyakov et al. | Mar 2010 | A1 |
20100083376 | Pereira et al. | Apr 2010 | A1 |
20100115621 | Staniford et al. | May 2010 | A1 |
20100132038 | Zaitsev | May 2010 | A1 |
20100154056 | Smith et al. | Jun 2010 | A1 |
20100180344 | Malyshev et al. | Jul 2010 | A1 |
20100192223 | Ismael et al. | Jul 2010 | A1 |
20100220863 | Dupaquis et al. | Sep 2010 | A1 |
20100235831 | Dittmer | Sep 2010 | A1 |
20100251104 | Massand | Sep 2010 | A1 |
20100281102 | Chinta et al. | Nov 2010 | A1 |
20100281541 | Stolfo et al. | Nov 2010 | A1 |
20100281542 | Stolfo et al. | Nov 2010 | A1 |
20100287260 | Peterson et al. | Nov 2010 | A1 |
20100299754 | Amit et al. | Nov 2010 | A1 |
20100306173 | Frank | Dec 2010 | A1 |
20110004737 | Greenebaum | Jan 2011 | A1 |
20110025504 | Lyon et al. | Feb 2011 | A1 |
20110041179 | St Hlberg | Feb 2011 | A1 |
20110047594 | Mahaffey et al. | Feb 2011 | A1 |
20110047620 | Mahaffey et al. | Feb 2011 | A1 |
20110055907 | Narasimhan et al. | Mar 2011 | A1 |
20110078794 | Manni et al. | Mar 2011 | A1 |
20110093951 | Aziz | Apr 2011 | A1 |
20110099620 | Stavrou et al. | Apr 2011 | A1 |
20110099633 | Aziz | Apr 2011 | A1 |
20110099635 | Silberman et al. | Apr 2011 | A1 |
20110113231 | Kaminsky | May 2011 | A1 |
20110145918 | Jung et al. | Jun 2011 | A1 |
20110145920 | Mahaffey et al. | Jun 2011 | A1 |
20110145934 | Abramovici et al. | Jun 2011 | A1 |
20110167493 | Song et al. | Jul 2011 | A1 |
20110167494 | Bowen et al. | Jul 2011 | A1 |
20110173213 | Frazier et al. | Jul 2011 | A1 |
20110173460 | Ito et al. | Jul 2011 | A1 |
20110219449 | St. Neitzel et al. | Sep 2011 | A1 |
20110219450 | McDougal et al. | Sep 2011 | A1 |
20110225624 | Sawhney et al. | Sep 2011 | A1 |
20110225655 | Niemela et al. | Sep 2011 | A1 |
20110247072 | Staniford et al. | Oct 2011 | A1 |
20110265182 | Peinado et al. | Oct 2011 | A1 |
20110289582 | Kejriwal et al. | Nov 2011 | A1 |
20110302587 | Nishikawa et al. | Dec 2011 | A1 |
20110307954 | Melnik et al. | Dec 2011 | A1 |
20110307955 | Kaplan et al. | Dec 2011 | A1 |
20110307956 | Yermakov et al. | Dec 2011 | A1 |
20110314546 | Aziz et al. | Dec 2011 | A1 |
20120023593 | Puder et al. | Jan 2012 | A1 |
20120054869 | Yen et al. | Mar 2012 | A1 |
20120066698 | Yanoo | Mar 2012 | A1 |
20120079596 | Thomas et al. | Mar 2012 | A1 |
20120084859 | Radinsky et al. | Apr 2012 | A1 |
20120096553 | Srivastava et al. | Apr 2012 | A1 |
20120110667 | Zubrilin et al. | May 2012 | A1 |
20120117652 | Manni et al. | May 2012 | A1 |
20120121154 | Xue et al. | May 2012 | A1 |
20120124426 | Maybee et al. | May 2012 | A1 |
20120174186 | Aziz et al. | Jul 2012 | A1 |
20120174196 | Bhogavilli et al. | Jul 2012 | A1 |
20120174218 | McCoy et al. | Jul 2012 | A1 |
20120198279 | Schroeder | Aug 2012 | A1 |
20120210423 | Friedrichs et al. | Aug 2012 | A1 |
20120222121 | Staniford et al. | Aug 2012 | A1 |
20120255015 | Sahita et al. | Oct 2012 | A1 |
20120255017 | Sallam | Oct 2012 | A1 |
20120260342 | Dube et al. | Oct 2012 | A1 |
20120266244 | Green et al. | Oct 2012 | A1 |
20120278886 | Luna | Nov 2012 | A1 |
20120297489 | Dequevy | Nov 2012 | A1 |
20120330801 | McDougal et al. | Dec 2012 | A1 |
20120331553 | Aziz et al. | Dec 2012 | A1 |
20130014259 | Gribble et al. | Jan 2013 | A1 |
20130036472 | Aziz | Feb 2013 | A1 |
20130047257 | Aziz | Feb 2013 | A1 |
20130074185 | McDougal et al. | Mar 2013 | A1 |
20130086684 | Mohler | Apr 2013 | A1 |
20130097699 | Balupari et al. | Apr 2013 | A1 |
20130097706 | Titonis et al. | Apr 2013 | A1 |
20130111587 | Goel et al. | May 2013 | A1 |
20130117852 | Stute | May 2013 | A1 |
20130117855 | Kim et al. | May 2013 | A1 |
20130139264 | Brinkley et al. | May 2013 | A1 |
20130160125 | Likhachev et al. | Jun 2013 | A1 |
20130160127 | Jeong et al. | Jun 2013 | A1 |
20130160130 | Mendelev et al. | Jun 2013 | A1 |
20130160131 | Madou et al. | Jun 2013 | A1 |
20130167236 | Sick | Jun 2013 | A1 |
20130174214 | Duncan | Jul 2013 | A1 |
20130185789 | Hagiwara et al. | Jul 2013 | A1 |
20130185795 | Winn et al. | Jul 2013 | A1 |
20130185798 | Saunders et al. | Jul 2013 | A1 |
20130191915 | Antonakakis et al. | Jul 2013 | A1 |
20130196649 | Paddon et al. | Aug 2013 | A1 |
20130227691 | Aziz et al. | Aug 2013 | A1 |
20130246370 | Bartram et al. | Sep 2013 | A1 |
20130247186 | LeMasters | Sep 2013 | A1 |
20130263260 | Mahaffey et al. | Oct 2013 | A1 |
20130291109 | Staniford et al. | Oct 2013 | A1 |
20130298243 | Kumar et al. | Nov 2013 | A1 |
20130318038 | Shiffer et al. | Nov 2013 | A1 |
20130318073 | Shiffer et al. | Nov 2013 | A1 |
20130325791 | Shiffer et al. | Dec 2013 | A1 |
20130325792 | Shiffer et al. | Dec 2013 | A1 |
20130325871 | Shiffer et al. | Dec 2013 | A1 |
20130325872 | Shiffer et al. | Dec 2013 | A1 |
20140032875 | Butler | Jan 2014 | A1 |
20140053260 | Gupta et al. | Feb 2014 | A1 |
20140053261 | Gupta et al. | Feb 2014 | A1 |
20140130158 | Wang et al. | May 2014 | A1 |
20140137180 | Lukacs et al. | May 2014 | A1 |
20140157420 | Guarnieri | Jun 2014 | A1 |
20140169762 | Ryu | Jun 2014 | A1 |
20140179360 | Jackson et al. | Jun 2014 | A1 |
20140181131 | Ross | Jun 2014 | A1 |
20140189687 | Jung et al. | Jul 2014 | A1 |
20140189866 | Shiffer et al. | Jul 2014 | A1 |
20140189882 | Jung et al. | Jul 2014 | A1 |
20140237600 | Silberman et al. | Aug 2014 | A1 |
20140280245 | Wilson | Sep 2014 | A1 |
20140283037 | Sikorski et al. | Sep 2014 | A1 |
20140283063 | Thompson et al. | Sep 2014 | A1 |
20140298460 | Xue | Oct 2014 | A1 |
20140328204 | Klotsche et al. | Nov 2014 | A1 |
20140337836 | Ismael | Nov 2014 | A1 |
20140344926 | Cunningham et al. | Nov 2014 | A1 |
20140351935 | Shao et al. | Nov 2014 | A1 |
20140380473 | Bu et al. | Dec 2014 | A1 |
20140380474 | Paithane et al. | Dec 2014 | A1 |
20150007312 | Pidathala et al. | Jan 2015 | A1 |
20150096022 | Vincent et al. | Apr 2015 | A1 |
20150096023 | Mesdaq et al. | Apr 2015 | A1 |
20150096024 | Haq et al. | Apr 2015 | A1 |
20150096025 | Ismael | Apr 2015 | A1 |
20150121526 | McLarnon | Apr 2015 | A1 |
20150156203 | Giura | Jun 2015 | A1 |
20150180886 | Staniford et al. | Jun 2015 | A1 |
20150186645 | Aziz et al. | Jul 2015 | A1 |
20150199513 | Ismael et al. | Jul 2015 | A1 |
20150199531 | Ismael et al. | Jul 2015 | A1 |
20150199532 | Ismael et al. | Jul 2015 | A1 |
20150220735 | Paithane et al. | Aug 2015 | A1 |
20150372980 | Eyada | Dec 2015 | A1 |
20160004869 | Ismael et al. | Jan 2016 | A1 |
20160006756 | Ismael et al. | Jan 2016 | A1 |
20160044000 | Cunningham | Feb 2016 | A1 |
20160127393 | Aziz et al. | May 2016 | A1 |
20160191547 | Zafar et al. | Jun 2016 | A1 |
20160191550 | Ismael et al. | Jun 2016 | A1 |
20160261612 | Mesdaq et al. | Sep 2016 | A1 |
20160285914 | Singh | Sep 2016 | A1 |
20160301703 | Aziz | Oct 2016 | A1 |
20160330215 | Gafni | Nov 2016 | A1 |
20160335110 | Paithane et al. | Nov 2016 | A1 |
20170083703 | Abbasi et al. | Mar 2017 | A1 |
20180013770 | Ismael | Jan 2018 | A1 |
20180048660 | Paithane et al. | Feb 2018 | A1 |
20180121316 | Ismael et al. | May 2018 | A1 |
20180288077 | Siddiqui et al. | Oct 2018 | A1 |
Number | Date | Country |
---|---|---|
2439806 | Jan 2008 | GB |
2490431 | Oct 2012 | GB |
0206928 | Jan 2002 | WO |
0223805 | Mar 2002 | WO |
2007117636 | Oct 2007 | WO |
2008041950 | Apr 2008 | WO |
2011084431 | Jul 2011 | WO |
2011112348 | Sep 2011 | WO |
2012075336 | Jun 2012 | WO |
2012145066 | Oct 2012 | WO |
2013067505 | May 2013 | WO |
Entry |
---|
Venezia, Paul , “NetDetector Captures Intrusions”, InfoWorld Issue 27, (“Venezia”), (Jul. 14, 2003). |
Vladimir Getov: “Security as a Service in Smart Clouds—Opportunities and Concerns”, Computer Software and Applications Conference (COMPSAC), 2012 IEEE 36TH Annual, IEEE, Jul. 16, 2012 (Jul. 16, 2012). |
Wahid et al., Characterising the Evolution in Scanning Activity of Suspicious Hosts, Oct. 2009, Third International Conference on Network and System Security, pp. 344-350. |
Whyte, et al., “DNS-Based Detection of Scanning Works in an Enterprise Network”, Proceedings of the 12th Annual Network and Distributed System Security Symposium, (Feb. 2005), 15 pages. |
Williamson, Matthew M., “Throttling Viruses: Restricting Propagation to Defeat Malicious Mobile Code”, ACSAC Conference, Las Vegas, NV, USA, (Dec. 2002), pp. 1-9. |
Yuhei Kawakoya et al: “Memory behavior-based automatic malware unpacking in stealth debugging environment”, Malicious and Unwanted Software (Malware), 2010 5th International Conference on, IEEE, Piscataway, NJ, USA, Oct. 19, 2010, pp. 39-46, XP031833827, ISBN:978-1-4244-8-9353-1. |
Zhang et al., The Effects of Threading, Infection Time, and Multiple-Attacker Collaboration on Malware Propagation, Sep. 2009, IEEE 28th International Symposium on Reliable Distributed Systems, pp. 73-82. |
“Mining Specification of Malicious Behavior”—Jha et al, UCSB, Sep. 2007 https://www.cs.ucsb.edu/.about.chris/research/doc/esec07.sub.-mining.pdf-. |
“Network Security: NetDetector—Network Intrusion Forensic System (NIFS) Whitepaper”, (“NetDetector Whitepaper”), (2003). |
“When Virtual is Better Than Real”, IEEEXplore Digital Library, available at, http://ieeexplore.ieee.org/xpl/articleDetails.isp?reload=true&arnumbe- r=990073, (Dec. 7, 2013). |
Abdullah, et al., Visualizing Network Data for Intrusion Detection, 2005 IEEE Workshop on Information Assurance and Security, pp. 100-108. |
Adetoye, Adedayo , et al., “Network Intrusion Detection & Response System”, (“Adetoye”), (Sep. 2003). |
Apostolopoulos, George; hassapis, Constantinos; “V-eM: A cluster of Virtual Machines for Robust, Detailed, and High-Performance Network Emulation”, 14th IEEE International Symposium on Modeling, Analysis, and Simulation of Computer and Telecommunication Systems, Sep. 11-14, 2006, pp. 117-126. |
Aura, Tuomas, “Scanning electronic documents for personally identifiable information”, Proceedings of the 5th ACM workshop on Privacy in electronic society. ACM, 2006. |
Baecher, “The Nepenthes Platform: An Efficient Approach to collect Malware”, Springer-verlag Berlin Heidelberg, (2006), pp. 165-184. |
Bayer, et al., “Dynamic Analysis of Malicious Code”, J Comput Virol, Springer-Verlag, France., (2006), pp. 67-77. |
Boubalos, Chris , “extracting syslog data out of raw pcap dumps, seclists.org, Honeypots mailing list archives”, available at http://seclists.org/honeypots/2003/q2/319 (“Boubalos”), (Jun. 5, 2003). |
Chaudet, C. , et al., “Optimal Positioning of Active and Passive Monitoring Devices”, International Conference on Emerging Networking Experiments and Technologies, Proceedings of the 2005 ACM Conference on Emerging Network Experiment and Technology, CoNEXT '05, Toulousse, France, (Oct. 2005), pp. 71-82. |
Chen, P. M. and Noble, B. D., “When Virtual is Better Than Real, Department of Electrical Engineering and Computer Science”, University of Michigan (“Chen”) (2001). |
Cisco “Intrusion Prevention for the Cisco ASA 5500-x Series” Data Sheet (2012). |
Cohen, M.I. , “PyFlag—An advanced network forensic framework”, Digital investigation 5, Elsevier, (2008), pp. S112-S120. |
Costa, M. , et al., “Vigilante: End-to-End Containment of Internet Worms”, SOSP '05, Association for Computing Machinery, Inc., Brighton U.K., (Oct. 23-26, 2005). |
Didier Stevens, “Malicious PDF Documents Explained”, Security & Privacy, IEEE, IEEE Service Center, Los Alamitos, CA, US, vol. 9, No. 1, Jan. 1, 2011, pp. 80-82, XP011329453, ISSN: 1540-7993, DOI: 10.1109/MSP.2011.14. |
Distler, “Malware Analysis: An Introduction”, SANS Institute InfoSec Reading Room, SANS Institute, (2007). |
Dunlap, George W. , et al., “ReVirt: Enabling Intrusion Analysis through Virtual-Machine Logging and Replay”, Proceeding of the 5th Symposium on Operating Systems Design and Implementation, USENIX Association, (“Dunlap”), (Dec. 9, 2002). |
FireEye Malware Analysis & Exchange Network, Malware Protection System, FireEye Inc., 2010. |
FireEye Malware Analysis, Modern Malware Forensics, FireEye Inc., 2010. |
FireEye v.6.0 Security Target, pp. 1-35, Version 1.1, FireEye Inc., May 2011. |
Goel, et al., Reconstructing System State for Intrusion Analysis, Apr. 2008 SIGOPS Operating Systems Review, vol. 42 Issue 3, pp. 21-28. |
Gregg Keizer: “Microsoft's HoneyMonkeys Show Patching Windows Works”, Aug. 8, 2005, XP055143386, Retrieved from the Internet: URL:http://www.informationweek.com/microsofts-honeymonkeys-show-patching-windows-works/d/d-id/1035069? [retrieved on Jun. 1, 2016]. |
Heng Yin et al, Panorama: Capturing System-Wide Information Flow for Malware Detection and Analysis, Research Showcase @ CMU, Carnegie Mellon University, 2007. |
Hiroshi Shinotsuka, Malware Authors Using New Techniques to Evade Automated Threat Analysis Systems, Oct. 26, 2012, http://www.symantec.com/connect/blogs/, pp. 1-4. |
Idika et al., A-Survey-of-Malware-Detection-Techniques, Feb. 2, 2007, Department of Computer Science, Purdue University. |
Isohara, Takamasa, Keisuke Takemori, and Ayumu Kubota. “Kernel-based behavior analysis for android malware detection.” Computational intelligence and Security (CIS), 2011 Seventh International Conference on. IEEE, 2011. |
Kaeo, Merike , “Designing Network Security”, (“Kaeo”), (Nov. 2003). |
Kevin A Roundy et al: “Hybrid Analysis and Control of Malware”, Sep. 15, 2010, Recent Advances in Intrusion Detection, Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 317-338, XP019150454 ISBN:978-3-642-15511-6. |
Khaled Salah et al: “Using Cloud Computing to Implement a Security Overlay Network”, Security & Privacy, IEEE, IEEE Service Center, Los Alamitos, CA, US, vol. 11, No. 1, Jan. 1, 2013 (Jan. 1, 2013). |
Kim, H. , et al., “Autograph: Toward Automated, Distributed Worm Signature Detection”, Proceedings of the 13th Usenix Security Symposium (Security 2004), San Diego, (Aug. 2004), pp. 271-286. |
King, Samuel T., et al., “Operating System Support for Virtual Machines”, (“King”), (2003). |
Kreibich, C. , et al., “Honeycomb-Creating Intrusion Detection Signatures Using Honeypots”, 2nd Workshop on Hot Topics in Networks (HotNets-11), Boston, USA, (2003). |
Kristoff, J. , “Botnets, Detection and Mitigation: DNS-Based Techniques”, NU Security Day, (2005), 23 pages. |
Lastline Labs, The Threat of Evasive Malware, Feb. 25, 2013, Lastline Labs, pp. 1-8. |
Li et al., A VMM-Based System Call Interposition Framework for Program Monitoring, Dec. 2010, IEEE 16th International Conference on Parallel and Distributed Systems, pp. 706-711. |
Lindorfer, Martina, Clemens Kolbitsch, and Paolo Milani Comparetti. “Detecting environment-sensitive malware.” Recent Advances in Intrusion Detection. Springer Berlin Heidelberg, 2011. |
Marchette, David J., “Computer Intrusion Detection and Network Monitoring: A Statistical Viewpoint”, (“Marchette”), (2001). |
Moore, D. , et al., “Internet Quarantine: Requirements for Containing Self-Propagating Code”, INFOCOM, vol. 3, (Mar. 30-Apr. 3, 2003), pp. 1901-1910. |
Morales, Jose A., et al., ““Analyzing and exploiting network behaviors of malware.””, Security and Privacy in Communication Networks. Springer Berlin Heidelberg, 2010. 20-34. |
Mori, Detecting Unknown Computer Viruses, 2004, Springer-Verlag Berlin Heidelberg. |
Natvig, Kurt , “SANDBOXII: Internet”, Virus Bulletin Conference, (“Natvig”), (Sep. 2002). |
NetBIOS Working Group. Protocol Standard for a NetBIOS Service on a TCP/UDP transport: Concepts and Methods. STD 19, RFC 1001, Mar. 1987. |
Newsome, J. , et al., “Dynamic Taint Analysis for Automatic Detection, Analysis, and Signature Generation of Exploits on Commodity Software”, In Proceedings of the 12th Annual Network and Distributed System Security, Symposium (NDSS '05), (Feb. 2005). |
Nojiri, D. , et al., “Cooperation Response Strategies for Large Scale Attack Mitigation”, DARPA Information Survivability Conference and Exposition, vol. 1, (Apr. 22-24, 2003), pp. 293-302. |
Oberheide et al., CloudAV.sub.--N-Version Antivirus in the Network Cloud, 17th USENIX Security Symposium USENIX Security '08 Jul. 28-Aug. 1, 2008 San Jose, CA. |
Reiner Sailer, Enriquillo Valdez, Trent Jaeger, Roonald Perez, Leendert van Doorn, John Linwood Griffin, Stefan Berger., sHype: Secure Hypervisor Appraoch to Trusted Virtualized Systems (Feb. 2, 2005) (“Sailer”). |
Silicon Defense, “Worm Containment in the Internal Network”, (Mar. 2003), pp. 1-25. |
Singh, S. , et al., “Automated Worm Fingerprinting”, Proceedings of the ACM/USENIX Symposium on Operating System Design and Implementation, San Francisco, California, (Dec. 2004). |
Thomas H. Ptacek, and Timothy N. Newsham , “Insertion, Evasion, and Denial of Service: Eluding Network Intrusion Detection”, Secure Networks, (“Ptacek”), (Jan. 1998). |